Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2023-06-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于获得注射用盐酸吉西他滨药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for a specific pharmaceutical product from the National Medical Products Administration. It details the drug's basic information, approval status, and potential impact on the company. The document is short (1029 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-06-19 Chinese
北京双鹭药业股份有限公司关于高级管理人员减持计划到期后拟继续减持股份的预披露公告
Director's Dealing Classification · 95% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding a senior management personnel's (Ms. Liang Shujie, director and board secretary) plan to continue reducing her shareholding after the expiration of a previous reduction plan. It details the share reduction plan, the number of shares reduced, the schedule, and compliance with relevant securities laws and stock exchange rules. The document includes tables showing shareholding before and after reduction and confirms that the reduction will not affect company control or governance. The content is focused on insider share transactions by a director and senior management, specifically a pre-disclosure of a share reduction plan and its progress. It is not a financial report, earnings release, or regulatory certification. It is not a general regulatory filing or announcement of a report publication. The document fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is about 3100 characters, consistent with a detailed insider dealing announcement rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2023-06-12 Chinese
北京双鹭药业股份有限公司关于公司第二大股东减持计划实施完成的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholding reduction plan by the company's second largest shareholder. It details the number of shares reduced, the methods of reduction, and the impact on shareholding percentages. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, as it reports changes in significant share ownership levels. The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2023-05-26 Chinese
北京双鹭药业股份有限公司2022年年度股东大会的法律意见
Regulatory Filings
2023-05-25 Chinese
北京双鹭药业股份有限公司2022年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022年度股东大会决议公告" which translates to "2022 Annual General Meeting Resolution Announcement." It details the convening and attendance of the 2022 Annual General Meeting (AGM), the voting results on various proposals including the 2022 annual reports, financial statements, profit distribution plan, auditor appointment, and other corporate matters. It also includes legal opinions on the meeting's validity and independent directors' reports. The document is a formal announcement of the resolutions passed at the AGM, including voting results, rather than the full annual report or financial statements themselves. The length is about 4544 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-25 Chinese
北京双鹭药业股份有限公司关于召开2022年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2022 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, agenda items including the 2022 annual report and financial statements, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for shareholders to participate in the AGM. The document length is 4241 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM.
2023-05-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.